Immatics/$IMTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Immatics
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Ticker
$IMTX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
646
ISIN
NL0015285941
Website
Immatics Metrics
BasicAdvanced
$717M
-
-$0.24
0.87
-
Price and volume
Market cap
$717M
Beta
0.87
52-week high
$13.02
52-week low
$3.30
Average daily volume
732K
Financial strength
Current ratio
10.284
Quick ratio
9.868
Long term debt to equity
2.859
Total debt to equity
3.427
Interest coverage (TTM)
-64.31%
Profitability
EBITDA (TTM)
-60.639
Gross margin (TTM)
-9.53%
Net profit margin (TTM)
-15.54%
Operating margin (TTM)
-41.98%
Effective tax rate (TTM)
-25.96%
Revenue per employee (TTM)
$258,210
Management effectiveness
Return on assets (TTM)
-5.84%
Return on equity (TTM)
-4.78%
Valuation
Price to revenue (TTM)
3.886
Price to book
1.34
Price to tangible book (TTM)
1.34
Price to free cash flow (TTM)
-3.294
Free cash flow yield (TTM)
-30.36%
Free cash flow per share (TTM)
-179.11%
Growth
Revenue change (TTM)
93.57%
Earnings per share change (TTM)
-77.94%
3-year revenue growth (CAGR)
3.43%
3-year earnings per share growth (CAGR)
-5.28%
What the Analysts think about Immatics
Analyst ratings (Buy, Hold, Sell) for Immatics stock.
Bulls say / Bears say
Immatics reported a net profit of €15.2 million for the year ended December 31, 2024, a significant turnaround from a net loss of €94.6 million in 2023, primarily due to increased revenue from collaboration agreements. (Immatics N.V.)
The company announced positive initial clinical data from the Phase 1 trial of TCER® IMA402, showing favorable tolerability and potential efficacy in PRAME-positive patients, indicating promising advancements in their pipeline. (Nasdaq)
Immatics successfully completed a $150 million public offering in October 2024, strengthening its financial position and providing capital to advance its clinical programs. (StockTitan)
Analysts at Cantor Fitzgerald have decreased their FY2025 EPS estimates for Immatics, now anticipating a loss of $1.53 per share, down from a prior forecast of $1.34, indicating concerns about future profitability. (Defense World)
Despite increased revenue, Immatics faced substantial research and development expenses, contributing to a loss before taxes of €2.4 million for Q3 2024, highlighting ongoing financial challenges. (StockNews)
The company's shares have experienced volatility, with a decrease of 19.85% since Wellington Management Group LLP's acquisition of additional shares in September 2024, reflecting market uncertainty. (GuruFocus)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
Immatics Financial Performance
Revenues and expenses
Immatics Earnings Performance
Company profitability
Immatics News
AllArticlesVideos
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
GlobeNewsWire·1 month ago
Immatics Announces First Quarter 2025 Financial Results and Business Update
GlobeNewsWire·2 months ago
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Immatics stock?
Immatics (IMTX) has a market cap of $717M as of July 10, 2025.
What is the P/E ratio for Immatics stock?
The price to earnings (P/E) ratio for Immatics (IMTX) stock is 0 as of July 10, 2025.
Does Immatics stock pay dividends?
No, Immatics (IMTX) stock does not pay dividends to its shareholders as of July 10, 2025.
When is the next Immatics dividend payment date?
Immatics (IMTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Immatics?
Immatics (IMTX) has a beta rating of 0.87. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.